TranS1, a Nasdaq-listed medical device maker, has agreed to acquire Baxano, a US-based developer of spinal devices backed by healthcare provider Kaiser Permanente’s eponymous corporate venturing unit. TranS1 is paying $23.6m, including $550,000 in cash on Baxano’s balance sheet and refinancing $3m of the target’s debt. Baxano had raised $58.6m from Kaiser Permanente Ventures and…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
